Effect of anti-inflammatory therapy of axial spondyloarthritis on cardiovascular risk
Clinical review for general practice · 19.06.2026 · 7 (4) · 73-78
DOI: 10.47407/kr2026.7.4.00825 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical review for general practice, online erschienen am 19.06.2026. Verfasst von Anife S Gaffarova und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Spondyloarthritis (SpA) is a group of inflammatory joint diseases with axial and peripheral skeletal involvement, characterized by a progressive course and the development of extra-articular manifestations like psoriasis, eyes’ pathology (uveitis, iridocyclitis) and inflammatory bowel disease (ulcerative colitis, Crohn's disease). The most frequent comorbid condition and cause of death in SpA is cardiovascular disease (CVD). Studies have shown a decrease in the incidence of CVD with a decrease in cumulative inflammatory load due to adequate therapy of SpA. At the same time, treatment of SpA is associated with the use of NSAIDs as first-line basic therapy, known to have an adverse effect on cardiovascular risk (CVR), mainly due to an increase of arterial hypertension frequency. In studies, the use of NSAIDs in patients with SpA has been shown to be associated with a reduction in CVR by reducing of disease activity, and the on-demand usage of NSAIDs was associated with a reduction in life expectancy, despite a 12% increase of AH incidence due to NSAIDs use. Conventional synthetic DMARDs as a sulfasalazine and methotrexate have an indirect positive effect on the reduction of CVR by reducing the cumulative negative effect of inflammation on CVR, the direct effect on the reduction of CVR has not been studied. TNFα inhibitors also reduce laboratory and clinical SpA activity, indirectly reducing CVR. It is shown that IL-17 is involved in induction of atherogenesis, therefore, IL-17 inhibition not only allows to reduce SpA activity, but also directly additionally reduces CVR, which is especially relevant for patients with SpA with traditional CVR factors. In general, adequate anti-inflammatory therapy of SpA reduces CVR by reducing the laboratory and clinical activity of the disease, and biologic DMARDs can have a direct protective effect by inhibiting atherogenesis. Keywords: axial spondyloarthritis, cardiovascular disease, non-steroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs.
Zitieren
APA
Gaffarova, A. S., Beloglazov, V. A., Yatskov, I. A., Petrov, A. V., & Zayaeva, A. A. (2026). Effect of anti-inflammatory therapy of axial spondyloarthritis on cardiovascular risk. Clinical review for general practice, 7(4), 73-78. https://doi.org/10.47407/kr2026.7.4.00825
Vancouver
Gaffarova AS, Beloglazov VA, Yatskov IA, Petrov AV, Zayaeva AA. Effect of anti-inflammatory therapy of axial spondyloarthritis on cardiovascular risk. Clinical review for general practice. 2026;7(4):73-78. doi:10.47407/kr2026.7.4.00825
BibTeX
@article{Gaffarova2026,
author = {Gaffarova, Anife S and Beloglazov, Vladimir A and Yatskov, Igor A and Petrov, Andrey V and Zayaeva, Anna A},
title = {Effect of anti-inflammatory therapy of axial spondyloarthritis on cardiovascular risk},
journal = {Clinical review for general practice},
year = {2026},
volume = {7},
number = {4},
pages = {73--78},
doi = {10.47407/kr2026.7.4.00825}
}
EUVIMED